Additionally, two patients with CASPR2 encephalitis and one patient with GAD65-associated encephalitis showed immediate and sustained clinical improvements, along with a decrease in antibody levels, after receiving TCZ as initial therapy [67–69]. This evidence concerns the gene GAD2 and viral encephalitis.